Sanofi france - activities

Coronavirus : le Kevzara peu efficace comme traitement au virus selon SanofiCoronavirus : le Kevzara peu efficace comme traitement au virus selon SanofiCoronavirus : le Kevzara peu efficace comme traitement au virus selon SanofiCoronavirus : le Kevzara peu efficace comme traitement au virus selon Sanofi

Covid: Kevzara (sarilumab) underperforming as a therapy, according to an AP-HP study

According to an AP-HP study issued this November 23, 2021, Kevzara (sarilumab) - a potential cure to Covid - does not seem to have delivered conclusive results as for its effectiveness to avoid deaths after hospitalization. The study confirms results of the clinical trial led by Sanofi who announced in September 2020 they were ending their clinical trial after results of this study were inconclusive.
Covid : Sanofi va aider Pfizer à produire son vaccin en EuropeCovid : Sanofi va aider Pfizer à produire son vaccin en EuropeCovid : Sanofi va aider Pfizer à produire son vaccin en EuropeCovid : Sanofi va aider Pfizer à produire son vaccin en Europe

Covid: Sanofi to help Pfizer producing vaccine in Europe

This Tuesday January 26, in the evening, French laboratory Sanofi announced they will help rival Pfizer producing their vaccine in Europe as they are behind elaborating theirs. All in all, over 100 million doses are to be manufactured in Frankfurt by the end of 2021.